{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:56:29Z","timestamp":1789721789932,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":56,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.suronc.2020.08.030","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T11:50:25Z","timestamp":1598442625000},"page":"261-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT"],"prefix":"10.1016","volume":"35","author":[{"given":"M.J.L.","family":"Mastboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Lips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8871-9081","authenticated-orcid":false,"given":"K.","family":"van Langevelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2844-6253","authenticated-orcid":false,"given":"M.","family":"Mifsud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.A.","family":"Athanasou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.M.H.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.J.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.suronc.2020.08.030_bib1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.suronc.2020.08.030_bib2","unstructured":"de St. Aubain S, van de Rijn M. Tenosynovial giant cell tumour, localized type. In: Fletcher CDM BJ, Hogendoorn PCW, Mertens F, editor. WHO Classification of Tumours of Soft Tissue and Bone. 5. 4 ed2013. p. 100-101."},{"key":"10.1016\/j.suronc.2020.08.030_bib3","unstructured":"de St. Aubain S, van de Rijn M. Tenosynovial giant cell tumour, diffuse type. In: Fletcher CDM BJ, Hogendoorn PCW, Mertens F, editor. WHO Classification of Tumours of Soft Tissue and Bone. 52013. p. 102-103."},{"key":"10.1016\/j.suronc.2020.08.030_bib4","first-page":"1","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors","author":"Mastboom","year":"2017","journal-title":"Acta Orthop."},{"issue":"3","key":"10.1016\/j.suronc.2020.08.030_bib5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1302\/0301-620X.101B3.BJJ-2018-0804.R1","article-title":"The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function","volume":"101-B","author":"Verspoor","year":"2019","journal-title":"Bone Joint Lett. J"},{"issue":"4","key":"10.1016\/j.suronc.2020.08.030_bib6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","article-title":"Patient-reported symptoms of tenosynovial giant cell tumors","volume":"38","author":"Gelhorn","year":"2016","journal-title":"Clin. Therapeut."},{"issue":"2","key":"10.1016\/j.suronc.2020.08.030_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00259-016-3509-z","article-title":"The role of FDG PET\/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas","volume":"44","author":"Palmerini","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"6","key":"10.1016\/j.suronc.2020.08.030_bib8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","article-title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study","volume":"20","author":"Mastboom","year":"2019","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.suronc.2020.08.030_bib9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jso.23220","article-title":"A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal","volume":"107","author":"van der Heijden","year":"2013","journal-title":"J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.suronc.2020.08.030_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.knee.2017.04.019","article-title":"Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis","volume":"24","author":"Houdek","year":"2017","journal-title":"Knee"},{"issue":"2","key":"10.1016\/j.suronc.2020.08.030_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11864-015-0385-x","article-title":"Current systemic treatment options for tenosynovial giant cell tumor\/pigmented villonodular synovitis: targeting the CSF1\/CSF1R Axis","volume":"17","author":"Brahmi","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"issue":"8","key":"10.1016\/j.suronc.2020.08.030_bib12","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","article-title":"Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib","volume":"105","author":"Dewar","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.suronc.2020.08.030_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/sj.onc.1209007","article-title":"FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance","volume":"25","author":"Taylor","year":"2006","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.suronc.2020.08.030_bib14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/annonc\/mdn033","article-title":"Complete response to imatinib in relapsing pigmented villonodular synovitis\/tenosynovial giant cell tumor (PVNS\/TGCT)","volume":"19","author":"Blay","year":"2008","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"issue":"6","key":"10.1016\/j.suronc.2020.08.030_bib15","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.26409","article-title":"Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis","volume":"118","author":"Cassier","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.suronc.2020.08.030_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2045-3329-3-8","article-title":"Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib","volume":"3","author":"Stacchiotti","year":"2013","journal-title":"Clin. Sarcoma Res."},{"issue":"1","key":"10.1016\/j.suronc.2020.08.030_bib17","doi-asserted-by":"crossref","first-page":"14551","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci. Rep."},{"issue":"10197","key":"10.1016\/j.suronc.2020.08.030_bib18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.suronc.2020.08.030_bib19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.suronc.2018.07.002","article-title":"Severity classification of tenosynovial giant cell tumours on MR imaging","volume":"27","author":"Mastboom","year":"2018","journal-title":"Surgical oncology"},{"issue":"5","key":"10.1016\/j.suronc.2020.08.030_bib20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.suronc.2020.08.030_bib21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","article-title":"Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy","volume":"31","author":"Kinahan","year":"2010","journal-title":"Semin. Ultrasound CT MR"},{"issue":"3","key":"10.1016\/j.suronc.2020.08.030_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1590\/0100-3984.2013.1887","article-title":"The importance of PET\/CT in the evaluation of patients with Ewing tumors","volume":"48","author":"Guimaraes","year":"2015","journal-title":"Radiol. Bras."},{"issue":"9","key":"10.1016\/j.suronc.2020.08.030_bib23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat. Med."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740420303807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740420303807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:20:00Z","timestamp":1760757600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740420303807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":23,"alternative-id":["S0960740420303807"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2020.08.030","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2020.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}